Qyuns Therapeutics Co., Ltd. (HKG:2509)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
20.64
+0.84 (4.24%)
Feb 13, 2026, 4:08 PM HKT
Market Cap4.45B +190.2%
Revenue (ttm)351.04M +613.2%
Net Income-210.16M
EPS-0.95
Shares Out224.57M
PE Ration/a
Forward PE17.46
Dividendn/a
Ex-Dividend Daten/a
Volume254,200
Average Volume241,812
Open19.52
Previous Close19.80
Day's Range19.30 - 20.98
52-Week Range6.30 - 36.50
Betan/a
RSI46.11
Earnings DateMar 27, 2026

About Qyuns Therapeutics

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which is in Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p49 inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 337
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2509
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements